Validity of the Functional Classification of the Upper Extremities for Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Validity of the Functional Classification of the Upper Extremities for Duchenne Muscular Dystrophy

Published:2024 Issue:0 Volume:9 Page:n/a
ISSN:2432-1354
Container-title:Progress in Rehabilitation Medicine
language:en
Short-container-title:PRM

Author:

Miyazaki Yuta¹²,Hara Takatoshi¹³,Hagiwara Kazuki¹²,Nakamura Takuya¹²,Kamimura Akiko¹,Takeshita Eri⁴,Komaki Hirofumi⁴⁵,Mizuno Katsuhiro⁶,Tsuji Tetsuya²,Abo Masahiro³

Affiliation:

1. Department of Rehabilitation Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

2. Department of Rehabilitation Medicine, Keio University School of Medicine, Tokyo, Japan

3. Department of Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo, Japan

4. Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

5. Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan

6. Department of Rehabilitation Medicine, Tokai University School of Medicine, Hiratsuka, Japan

Publisher

Japanese Association of Rehabilitation Medicine

Link

https://www.jstage.jst.go.jp/article/prm/9/0/9_20240016/_pdf

Reference23 articles.

1. 1. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251–267. PMID:29395989, DOI:10.1016/S1474-4422(18)30024-3

2. 2. Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Takeshita E, Iwata Y, Yajima H, Egawa Y, Toramoto T, Tajima M, Takeda S: Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1/2 study. Ann Clin Transl Neurol 2020;7:2393–2408. PMID:33285037, DOI:10.1002/acn3.51235

3. 3. Elangkovan N, Dickson G: Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis 2021;8:S303–S316. PMID:34511510, DOI:10.3233/JND-210678

4. 4. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K, TREAT-NMD Neuromuscular Network: Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 2008;18:894–903. PMID:18818076, DOI:10.1016/j.nmd.2008.07.003

5. 5. Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S: The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989;31:341–352. PMID:2753238, DOI:10.1111/j.1469-8749.1989.tb04003.x